{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"33.3"},{"groupId":"OG003","value":"60.0"},{"groupId":"OG004","value":"75.0"},{"groupId":"OG005","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"AESIs were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. AESIs included the following: Grade ≥ 1 retinal vein occlusion; Grade ≥ 2 visual disturbances (including events suggestive of serous retinopathy); Grade ≥ 3 rash for \\> 7 days; Grade ≥ 3 diarrhea for \\> 3 days; Grade ≥ 2 left ventricular ejection fraction (LVEF) decrease; Grade 3 hepatotoxicity; any dose-limiting toxicity (DLT); cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (AST \\> 3 × baseline value \\[and above the upper limit of normal, ULN\\]) in combination with either an elevated bilirubin ( \\> 2 × ULN) or clinical jaundice; or suspected transmission of an infectious agent by either study drug.","groups":[{"description":"One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.","id":"OG000","title":"Not Assigned"},{"description":"Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG001","title":"COB 20 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG002","title":"COB 40 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG003","title":"COB 80 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.","id":"OG004","title":"COB 80 mg + GDC 400 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG005","title":"COB 100 mg + GDC 200 mg"}],"paramType":"NUMBER","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"Up to 15 months","title":"Percentage of Participants With at Least One Adverse Event of Special Interest","type":"PRIMARY","unitOfMeasure":"percentage of participants"}